Thermo Fisher Scientific Inc (TMO)
SuperavaliadaFundamental
61
Preço
$675.05
Capitalização de Mercado
$250.91B
Parte 1 · Quanto vale a empresa
Visão Geral
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$46.34B
Últimos 12 meses (até 27/06/2026)
Resultado Líquido
$6.97B
Últimos 12 meses (até 27/06/2026)
Fluxo de Caixa Livre
$6.29B
Capital Próprio Total
$53.41B
Passivo Total
$56.93B
Rácio de Liquidez
1.55
Cobertura de Juros
5.46
Dívida/EBITDA
3.62
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$437.42
Preço Atual
$675.05
Margem de Segurança
-54.3%
Intervalo de Valor Justo
$284.32 - $590.52
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
36.31
ROE
12.6%
Rácio P/B
4.74
P/FCF
34.11
Margem Bruta
-
ROIC
6.6%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
6.6%
WACC
8.3%
ROIC − WACC
-1.7 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (19)
- EPS shows upward trend
- EPS CAGR 13.95%
- Price CAGR 15.76%
- ROIC 6.6%
- Debt/Equity ratio
- Operating Margin 17.6%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 13.3%
- Revenue Growth 5Y 6.7%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 3.2%
- Earnings Quality (OCF/NI) 1.29
- Share Dilution -1.4%
- Piotroski F-Score 5/9
Reprovado (7)
- P/FCF 34.11
- P/B Ratio 4.74
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 16.99
- Net Margin Trend 15.0% vs 15.2%
Indisponível (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Marc N. Casper | Chairman & CEO | 57 |
| Mr. Gianluca Pettiti | President, COO & President of Products and Technologies | 46 |
| Mr. James R. Meyer | Senior VP & CFO | 45 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 45 |
| Mr. Ryan J. Snyder | Senior VP & Chief Information Officer | - |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer | - |
| Mr. Rafael Tejada | Vice President of Investor Relations | - |
| Mr. Thomas Bailey Shropshire Jr. | Senior VP and General Counsel | - |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | - |
| Mr. Alan J. Malus | Senior Vice President of Strategy & Corporate Development | 65 |
Risco de Auditoria
2
Risco do Conselho
7
Risco de Remuneração
10
Risco dos Direitos dos Acionistas
1
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-26
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-07-31
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-07-23
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for TMO, sourced from Markets Gazette.
- 5/25/2026POSITIVEIf You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today
An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.
- 3/12/2026POSITIVEHere's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.
- 3/2/2026NEUTRALHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.
via Markets Gazette